Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical study of ESP-01 in combination with low-dose gemcitabine in patients with high-grade serous ovarian cancer with tumors expressing defined genetic profiles

Next Previous
Search
Trial Profile

Clinical study of ESP-01 in combination with low-dose gemcitabine in patients with high-grade serous ovarian cancer with tumors expressing defined genetic profiles

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; LY 2880070 (Primary)
  • Indications Ovarian cancer
  • Focus Proof of concept; Therapeutic Use

    • Most Recent Events

    • 27 Feb 2023 New trial record
    • 21 Feb 2023 According to an Esperas Pharma media release, the company announced a follow-on investment by TVM Capital Life Science ("TVM") through its fund TVM Life Science Innovation I SCSp and the Fonds de solidarite FTQ (the "Fonds"). The company will conduct this study with the help of these funds. Enrollment is expected to start in March 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top